Telesis Bio, Inc., headquartered in the United States, is a pioneering company in the biotechnology sector, specialising in advanced DNA synthesis and genomic technologies. Founded in 2020, Telesis Bio has quickly established itself as a leader in the field, focusing on innovative solutions that enhance synthetic biology applications. The company’s flagship products, including the BioXp™ system, offer unique capabilities for rapid and scalable DNA synthesis, catering to a diverse range of industries such as pharmaceuticals, agriculture, and synthetic biology research. Telesis Bio's commitment to quality and efficiency has positioned it as a key player in the market, driving significant advancements in genetic engineering and molecular biology. With a strong emphasis on innovation, Telesis Bio continues to shape the future of biotechnology.
How does Telesis Bio, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Telesis Bio, Inc.'s score of 23 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Telesis Bio, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and climate commitments suggests that Telesis Bio may still be in the early stages of developing a comprehensive sustainability strategy. As the industry increasingly prioritises climate action, it will be essential for Telesis Bio to establish measurable targets and initiatives to align with global climate goals.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Telesis Bio, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
